IndiaMart
FIEO
Tirzepatide 45 mg Injection represents the highest strength formulation in the Tirzepatide series, offering exceptional therapeutic outcomes for patients with Type 2 Diabetes Mellitus (T2DM) and obesity. This once-weekly injectable provides enhanced glucose regulation, substantial weight reduction, and improved metabolic health. Manufactured and supplied globally by BLUEPILL EXPRESS, a trusted merchant exporter, Tirzepatide 45 mg is formulated in WHO-GMP and ISO-certified facilities located in India and China, ensuring flexibility in supply and compliance with international pharmaceutical standards.
Mechanism of Action:
Tirzepatide acts as a dual agonist of the Glucose-Dependent Insulinotropic Polypeptide (GIP) and Glucagon-Like Peptide-1 (GLP-1) receptors. Through this dual incretin mechanism, it enhances insulin secretion, suppresses glucagon release, delays gastric emptying, and improves satiety, resulting in both glycemic control and effective weight management. This combined effect significantly reduces HbA1c levels and body weight while supporting cardiovascular and metabolic health.
Key Features and Benefits:
High-strength 45 mg formulation designed for maximum therapeutic efficacy. Dual incretin activation ensures enhanced glycemic control and weight reduction. Once-weekly subcutaneous injection provides long-lasting effects and improved patient adherence. Demonstrated reduction in HbA1c by up to 2.9% and body weight reduction exceeding 20%. Manufactured under WHO-GMP and ISO-certified conditions in India and China. Ideal for bulk export, third-party manufacturing, and private labeling. Supported by complete export documentation and global regulatory compliance.
Therapeutic Indications:
Management of Type 2 Diabetes Mellitus in adults insufficiently controlled on diet, exercise, or other glucose-lowering agents. Chronic weight management in obese and overweight adults. Improvement of insulin sensitivity and reduction of cardiometabolic risk factors. Adjunct therapy for long-term metabolic balance and cardiovascular protection.
Dosage and Administration:
The recommended starting dose is 2.5 mg once weekly, gradually increased by 2.5 mg increments every 4 weeks to minimize gastrointestinal side effects. The maintenance dose of 45 mg is administered once weekly via subcutaneous injection into the abdomen, thigh, or upper arm. Injections should be performed under medical supervision. Administer the dose at the same time each week, with or without food. Do not exceed the prescribed dose.
Pharmacological Classification:
Therapeutic Category: Antidiabetic / Weight Management Agent.
Drug Class: Dual GIP and GLP-1 Receptor Agonist.
ATC Code: A10BJ06.
Precautions and Warnings:
Tirzepatide 45 mg Injection is not indicated for Type 1 Diabetes or diabetic ketoacidosis. Contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN2). Caution advised in patients with pancreatitis, renal impairment, or severe gastrointestinal disorders. Common side effects include nausea, vomiting, diarrhea, decreased appetite, and fatigue. Rare but serious adverse events include acute pancreatitis, allergic reactions, or hypoglycemia (when used with insulin or sulfonylureas). Not recommended during pregnancy or breastfeeding.
Storage and Handling:
Store at 2°C to 8°C (36°F to 46°F). Do not freeze. Protect from direct sunlight. Maintain cold-chain integrity during shipping and handling. Keep out of reach of children.
Manufacturing and Quality Compliance:
BLUEPILL EXPRESS ensures that Tirzepatide 45 mg Injection is manufactured in WHO-GMP and ISO-certified facilities in both India and China. Each batch undergoes rigorous quality control testing for potency, purity, sterility, and stability. The production facilities comply with global pharmacopoeial standards (IP/BP/USP) and Good Manufacturing Practices (GMP). Continuous process validation, microbiological monitoring, and temperature-controlled storage guarantee consistent product quality.
Export and Documentation Support:
BLUEPILL EXPRESS provides end-to-end export assistance, including documentation such as Certificate of Analysis (COA), Certificate of Origin (COO), Batch Manufacturing Record, MSDS, Stability Report, Cold Chain Validation, Packing List, and Commercial Invoice. The company also assists with regulatory dossier preparation, market registration support, and private-label branding for international distributors.
Why Choose BLUEPILL EXPRESS:
Recognized as a global merchant exporter, BLUEPILL EXPRESS offers dual manufacturing sources from India and China, ensuring supply reliability and competitive pricing. The company adheres to WHO-GMP, ISO, and international export compliance standards. With expertise in pharmaceutical logistics, private labeling, and regulatory affairs, BLUEPILL EXPRESS serves markets across Asia, Africa, Europe, the Middle East, and Latin America. Clients benefit from temperature-controlled air and sea shipments, custom packaging, and multi-language labeling options.
Clinical Efficacy and Global Recognition:
Clinical data demonstrates that Tirzepatide 45 mg Injection achieves an average HbA1c reduction of 2.9% and body weight loss exceeding 20%, positioning it among the most effective dual incretin therapies for diabetes and obesity. The formulation improves lipid profiles, insulin resistance, and cardiovascular outcomes, making it a cornerstone therapy for metabolic disease management.
Global Supply and Private Labeling:
BLUEPILL EXPRESS supplies Tirzepatide 45 mg Injection worldwide with full cold-chain logistics and documentation. The product is available for bulk orders, hospital supply, tenders, and private-label agreements, ensuring compliance with destination country regulations. Packaging and labeling can be customized according to market-specific languages and client branding requirements.
Conclusion:
Tirzepatide 45 mg Injection is a next-generation dual GIP and GLP-1 receptor agonist delivering exceptional efficacy in glycemic control and weight reduction. Through manufacturing facilities in India and China, BLUEPILL EXPRESS ensures international-standard production, export reliability, and regulatory compliance. As a trusted merchant exporter, BLUEPILL EXPRESS continues to serve global healthcare providers with innovative, high-quality, and cost-effective therapeutic solutions for Type 2 Diabetes and obesity management.
